drug · small molecule
Anti-inflammatory
pre_registrationupdated 5mo agoby AimMax Therapeutics Inc🔗 ChEMBL
community read0 votes
🐶 often sniffed alongside
top 2Small molecule drug with a maximum clinical stage of Phase 3 (across all indications), with 11 investigational indications.
targets
Mitogen-activated protein kinase 11Mitogen-activated protein kinase 14
all catalysts(0)
nothing on the calendar yet
Trials studying Anti-inflammatory
- N/ALong Term Extension of Safety and Efficacy of Vagus Nerve Stimulator in Patients With Rheumatoid Arthritis (RA)
- phase1Study to Evaluate Pharmacokinetic (PK), Safety and Tolerability of Cabotegravir (CAB) 400 Milligrams Per Milliliter (mg/mL) Formulation in Healthy Adult Participants
- phase2Autism Spectrum Disorder (ASD) Neurodevelopmental Disorder With Issues Social Behavior, Communication Issues, GI Dysfunction. Study is Multimodal Interventions Targeting These Pathways With cSVF, Stored MSCs, FMT and Diet Modification. Role of Autoimmunity, Gut-brain Issues, & Issues Examined.
- N/AEffect of a Combined Exercise and Anti-Inflammatory Nutritional Intervention in Frail Older Adults
- N/AAnti-Inflammatory Dietary Intervention for Rheumatoid Arthritis
News(10)
- Foghorn cuts 40% of workforceFollow along as BioSpace tracks job cuts and restructuring initiatives.biospace · 12h ago
- Connect’s Dupixent rival reduces COPD attacks by 85%, but misses a secondary goalConnect Biopharma has pointed to phase 2 data for its IL-4/IL-13 blocker as proof that the wannabe Dupixent rival can reduce respiratory attacks—although the study missed a secondary endpoint tied…fiercebiotech · 2d ago
- Opinion: STAT+: A moment of reckoning for preventive cardiology and the precision medicine revolution“The epidemiology and genetics of heart attack and stroke risk, for now, seem to have outpaced what more we can actually do about it,” writes cardiologist Vishal Khetpal.stat · 8d ago
- Amgen’s Horizon-acquired fusion protein eases Sjögren's severity in ph. 3 winAn investigational drug for the autoimmune condition Sjögren's disease has scored a phase 3 win for Amgen, marking a positive sign for the Horizon Therapeutics-acquired pipeline that has so far str…fiercebiotech · 10d ago
- NodThera, a decade-old NLRP3 player, plans Phase 3 and a rebrandAfter tinkering with the biology of the broadly appealing anti-inflammatory NLRP3 pathway, NodThera is now plotting its pivotal trial plans for 2027. The decade-old biotech said Wednesday it is reb…endpoints · 23d ago
- New data could widen use of AstraZeneca, Amgen immune disease drugTezspire succeeded in a study in eosinophilic esophagitis, which could become the drug’s third approved indication and unlock what’s viewed as a blockbuster opportunity.biopharma_dive · 1mo ago
- Generate Bio drops as data accidentally leaked ahead of European conferencePhase 1 data from Generate Biomedicines’ ongoing chronic obstructive pulmonary disease study demonstrated “rapid and sustained reductions” across four disease biomarkers.biospace · 1mo ago
- AstraZeneca, Amgen notch another late-stage win for Tezspire, this time in esophagitisAstraZeneca and Amgen co-develop and co-commercialize Tezspire under an April 2012 agreement. The partners are now planning another FDA submission for the asthma drug, which received an expansion i…biospace · 1mo ago
- China’s Haisco forms immunology biotech with up to $1.5B from American VCsHaisco Pharmaceutical Group has been on a deal hot streak this year, inking major deals with Eli Lilly, AbbVie and more. The new company will take on one of Haisco’s core immunology assets.biospace · 1mo ago
- Regeneron ends eye disease study due to antibody's safety profileThe discontinuation of the uveitis study adds to Regeneron’s series of clinical setbacks, including the Phase 3 failures of the Dupixent follow-up itepekimab and an investigational combo regimen fo…biospace · 1mo ago
Data sources
last refreshed 2h ago
Found something off?
comments(0)
5-min edit window · permanent after that